Literature DB >> 32788285

Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study.

Alberto Coppelli1, Rosa Giannarelli1, Michele Aragona1, Giuseppe Penno1,2, Marco Falcone2, Giusy Tiseo2, Lorenzo Ghiadoni2, Greta Barbieri2, Fabio Monzani2, Agostino Virdis2, Francesco Menichetti2, Stefano Del Prato.   

Abstract

OBJECTIVE: To explore whether at-admission hyperglycemia is associated with worse outcomes in patients hospitalized for coronavirus disease 2019 (COVID-19). RESEARCH DESIGN AND METHODS: Hospitalized COVID-19 patients (N = 271) were subdivided based on at-admission glycemic status: 1) glucose levels <7.78 mmol/L (NG) (N = 149 [55.0%]; median glucose 5.99 mmol/L [range 5.38-6.72]), 2) known diabetes mellitus (DM) (N = 56 [20.7%]; 9.18 mmol/L [7.67-12.71]), and 3) no diabetes and glucose levels ≥7.78 mmol/L (HG) (N = 66 [24.3%]; 8.57 mmol/L [8.18-10.47]).
RESULTS: Neutrophils were higher and lymphocytes and PaO2/FiO2 lower in HG than in DM and NG patients. DM and HG patients had higher D-dimer and worse inflammatory profile. Mortality was greater in HG (39.4% vs. 16.8%; unadjusted hazard ratio [HR] 2.20, 95% CI 1.27-3.81, P = 0.005) than in NG (16.8%) and marginally so in DM (28.6%; 1.73, 0.92-3.25, P = 0.086) patients. Upon multiple adjustments, only HG remained an independent predictor (HR 1.80, 95% CI 1.03-3.15, P = 0.04). After stratification by quintile of glucose levels, mortality was higher in quintile 4 (Q4) (3.57, 1.46-8.76, P = 0.005) and marginally in Q5 (29.6%) (2.32, 0.91-5.96, P = 0.079) vs. Q1.
CONCLUSIONS: Hyperglycemia is an independent factor associated with severe prognosis in people hospitalized for COVID-19.
© 2020 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32788285     DOI: 10.2337/dc20-1380

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  52 in total

1.  Elevated D-dimer and Adverse In-hospital Outcomes in COVID-19 Patients and Synergism with Hyperglycemia.

Authors:  Haowei Li; Shimin Chen; Shengshu Wang; Shanshan Yang; Wenzhe Cao; Shaohua Liu; Yang Song; Xuehang Li; Zhiqiang Li; Rongrong Li; Xiong Liu; Changjun Wang; Yong Chen; Fei Xie; Yao He; Miao Liu
Journal:  Infect Drug Resist       Date:  2022-07-12       Impact factor: 4.177

2.  Evaluation of the Effect of Biochemistry Parameters on the Clinical Course in COVID-19 Patients Who Received Tocilizumab Treatment.

Authors:  Faysal Duksal; Cengiz Burnik; Mehmet Mermer; Serkan Yavuz
Journal:  South Med J       Date:  2022-07       Impact factor: 0.810

3.  Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis.

Authors:  Danielle K Longmore; Jessica E Miller; Siroon Bekkering; Christoph Saner; Edin Mifsud; Yanshan Zhu; Richard Saffery; Alistair Nichol; Graham Colditz; Kirsty R Short; David P Burgner
Journal:  Diabetes Care       Date:  2021-04-15       Impact factor: 17.152

4.  Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: A sistematic review and meta-analysis.

Authors:  Francesco Prattichizzo; Paola de Candia; Antonio Nicolucci; Antonio Ceriello
Journal:  Diabetes Metab Res Rev       Date:  2021-05-28       Impact factor: 8.128

5.  Impact of COVID-19 on Youth With Type 2 Diabetes: Lessons Learned From a Pediatric Endocrinologist and a Psychologist.

Authors:  Cynthia E Muñoz; Lily C Chao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-27       Impact factor: 5.555

Review 6.  COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course.

Authors:  Cyril P Landstra; Eelco J P de Koning
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-17       Impact factor: 5.555

Review 7.  A Bittersweet Response to Infection in Diabetes; Targeting Neutrophils to Modify Inflammation and Improve Host Immunity.

Authors:  Rebecca Dowey; Ahmed Iqbal; Simon R Heller; Ian Sabroe; Lynne R Prince
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

8.  Effect of plasma glucose at admission on COVID-19 mortality: experience from a tertiary hospital.

Authors:  Bharat Kumar; Madhukar Mittal; Maya Gopalakrishnan; Mahendra K Garg; Sanjeev Misra
Journal:  Endocr Connect       Date:  2021-06-08       Impact factor: 3.335

9.  Impact of Prediabetes and Type-2 Diabetes on Outcomes in Patients with COVID-19.

Authors:  Jasbir Makker; Haozhe Sun; Harish Patel; Nikhitha Mantri; Maleeha Zahid; Sudharsan Gongati; Sneha Galiveeti; Sharon W Renner; Sridhar Chilimuri
Journal:  Int J Endocrinol       Date:  2021-06-16       Impact factor: 3.257

10.  Clinical outcomes of non-diabetic COVID-19 patients with different blood glucose levels: a nationwide Turkish study (TurCoGlycemia).

Authors:  Cem Haymana; Ibrahim Demirci; Ilker Tasci; Erman Cakal; Serpil Salman; Derun Ertugrul; Naim Ata; Ugur Unluturk; Selcuk Dagdelen; Aysegul Atmaca; Mustafa Sahin; Osman Celik; Tevfik Demir; Rifat Emral; Ibrahim Sahin; Murat Caglayan; Ilhan Satman; Alper Sonmez
Journal:  Endocrine       Date:  2021-06-22       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.